Neurocrine Biosciences, Inc.
NBIX
$102.88
-$5.43-5.01%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 341.30M | 385.90M | 339.20M | 369.70M | 249.70M |
| Total Depreciation and Amortization | 27.10M | 25.70M | 24.70M | 22.50M | 21.30M |
| Total Amortization of Deferred Charges | 0.00 | 0.00 | 138.40M | 88.70M | -- |
| Total Other Non-Cash Items | 246.20M | 232.00M | 153.70M | 110.40M | 90.70M |
| Change in Net Operating Assets | -19.20M | -167.20M | -125.60M | 54.10M | 28.20M |
| Cash from Operations | 595.40M | 476.40M | 530.40M | 645.40M | 389.90M |
| Capital Expenditure | -38.20M | -36.30M | -35.80M | -31.00M | -28.30M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -88.60M | -224.00M | -346.50M | -449.00M | -438.80M |
| Cash from Investing | -126.80M | -260.30M | -382.30M | -480.00M | -467.10M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -308.80M | -308.80M | -308.80M | -- | -- |
| Issuance of Common Stock | 122.10M | 147.50M | 139.90M | 127.00M | 65.30M |
| Repurchase of Common Stock | -300.00M | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -486.70M | -161.30M | -168.90M | 127.00M | 65.30M |
| Foreign Exchange rate Adjustments | 0.00 | 600.00K | 300.00K | 300.00K | 300.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -18.10M | 55.40M | -20.50M | 292.70M | -11.60M |
